Mannitol Adult Dose
For adults requiring mannitol for increased intracranial pressure or cerebral edema, administer 0.25 to 1 g/kg IV over 20-30 minutes, with doses typically repeated every 4-6 hours as needed, while monitoring serum osmolality to keep it below 320 mOsm/kg. 1
Dosing by Clinical Indication
Increased Intracranial Pressure / Brain Mass Reduction
The FDA-approved dosing range is 0.25 to 2 g/kg administered as a 15-25% solution over 30-60 minutes 1. However, clinical guidelines provide more nuanced recommendations:
- Standard dose: 0.25-0.5 g/kg IV over 20 minutes, repeated every 6 hours as needed 2
- Maximum single dose: 2 g/kg total 2
- Acute intracranial hypertensive crisis: Larger doses of 0.5-1 g/kg over 15 minutes may be appropriate 3
For traumatic brain injury specifically, the 2018 guidelines recommend mannitol 20% at a dose of 250 mOsm (approximately 0.5-1 g/kg) infused over 15-20 minutes to treat threatened intracranial hypertension or signs of brain herniation 4.
Acute Liver Failure with Intracranial Hypertension
Bolus dose of 0.5-1 g/kg IV is recommended when elevated ICP develops, which may be repeated once or twice provided serum osmolality remains below 320 mOsm/L 5.
Intraocular Pressure Reduction
The dosing mirrors that for ICP reduction: 0.25 to 2 g/kg as a 15-25% solution over 30-60 minutes 1.
Critical Monitoring Parameters
You must monitor serum osmolality every 6 hours and hold mannitol if:
Additional essential monitoring includes:
- Electrolytes (particularly sodium and potassium) every 4-6 hours
- Renal function
- Fluid balance with urinary catheter placement 3
- Intracranial pressure if monitored
Dose-Response Evidence
Recent research demonstrates clear dose-dependent effects:
- 1.0 g/kg appears optimal for supratentorial tumor surgery, providing satisfactory brain relaxation (67.7% success rate) with fewer adverse effects than higher doses 7
- 1.4 g/kg increases risk of moderate-to-severe postoperative cerebral edema compared to 1.0 g/kg 8
- Ultra-high doses (1.4 g/kg) in emergency settings with impending brain death showed improved outcomes in one trial, but this represents a specific salvage scenario 9
Administration Technique
- Administer through a filter - do not use solutions containing crystals 3
- Infusion rate: Typically over 15-30 minutes, though emergency situations may warrant faster administration
- Do not add to whole blood for transfusion 1
- Ensure adequate intravascular volume before administration to prevent hypotension
Common Pitfalls to Avoid
Hypovolemia: Mannitol causes osmotic diuresis; volume replacement is often necessary, particularly in patients with renal impairment who may require dialysis 5
Rebound cerebral edema: Can occur with abrupt discontinuation or excessive use; taper doses when discontinuing 6
Electrolyte disturbances: Moderate hyponatremia (125-130 mmol/L) occurs in up to 38.7% with 1.5 g/kg doses, and hyperkalemia in 12.9% 7
Prophylactic use is not indicated: Mannitol should be used to treat documented or clinically evident increased ICP, not prophylactically 5
Obesity considerations: Weight-based dosing yields higher than expected plasma concentrations in obese patients; consider using adjusted body weight 10
Pharmacokinetics Relevant to Dosing
- Elimination half-life: 0.5-2.5 hours in normal renal function 1
- Prolonged in renal impairment: Up to 36 hours in acute/end-stage renal failure 1
- Nonlinear kinetics: Central clearance differs between high-dose (0.07 L/min) and low-dose (0.04 L/min) groups, indicating dose-dependent pharmacokinetics 10
- 80% excreted unchanged in urine within 3 hours 1
Special Populations
Small or debilitated patients: Reduce initial dose to 500 mg/kg 1
Pediatric dosing (included for context, though question asks for adults): 1-2 g/kg or 30-60 g/m² over 30-60 minutes 3